Sandoz certified as Top Employer Europe 2017

  • Sandoz has been officially certified  by the Top Employers Institute for its exceptional employee offerings in Europe
  • The annual, international research undertaken by the Top Employers Institute recognizes leading employers around the world
  • This exclusive certification underlines our determination to attract and retain the best people from inside and outside our industry.”

Holzkirchen, February 8, 2017 – Sandoz, a Novartis division, is proud to announce that it has been officially certified  by the Top Employers …

/by

Sandoz confirms strategic commitment to drive access to medicines in Japan, with plan to double business by 2022

  • Japanese generic market set to expand rapidly, driven by government commitment to achieving sustainable high-quality healthcare
  • Sandoz Japan plans 70 new launches over next six years, which will account
    for ~40% of total sales by 2022
  • Growth drivers will include oncology, CNS and biosimilars

Tokyo, February 8, 2017 – Sandoz plans to double sales in Japan over the 2015 to 2022 period, as part of its long-term strategic plan to help drive access to hiqh-quality medicines in the Japanese market …

/by

Novartis delivered solid 2016 performance, with Growth Products[1] absorbing Gleevec US LOE; innovation momentum continued; announces share buyback

  • FY net sales (0% cc[2]) in line with prior year due to strong Growth Products performance
    • Cosentyx (USD 1.1 billion) reached blockbuster status
    • Entresto (USD 170 million) continued to grow steadily, following positive treatment guidelines in US and Europe and ongoing US field force expansion
    • Gilenya (USD 3.1 billion, +14% cc) delivered double-digit growth
    • Oncology grew 12% (cc) excluding Gleevec/Glivec, driven by new assets and Jakavi
    • Sandoz Biopharmaceuticals[1] grew 31% (cc) to reach USD 1.0 billion …
/by

New interim data demonstrate Sandoz proposed biosimilar rituximab has equivalent efficacy to reference product

  • ASSIST-FL trial demonstrates equivalent safety, efficacy, pharmacokinetics and pharmacodynamics of Sandoz proposed biosimilar rituximab (GP2013) to the reference product[1]
  • Interim data in over 600 adults show potential of GP2013 as an alternative rituximab[1]
  • Sandoz proposed biosimilar rituximab is the company’s first monoclonal antibody candidate

Holzkirchen, December 5, 2016 – Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced data from the ASSIST-FL trial. The confirmatory safety and efficacy …

/by

Sandoz to donate up to USD 10 million of high-quality generic medicines annually to Americares to increase access to medicines

Princeton, New Jersey, November 22, 2016. Sandoz today announced a collaboration to increase access to medicines by donating up to USD 10 million of stock annually to Americares, a health-focused relief and development organization that responds to people affected by poverty or disaster with life-changing health programs, medicine and medical supplies.

The initial donation will include over 25 Sandoz products for treatment for infections, cardiovascular conditions, eyecare, skin conditions and musculoskeletal pain. It is part of the global Sandoz commitment to …

/by

Innovative study with three treatment switches confirms Sandoz biosimilar etanercept has equivalent efficacy to originator

  • No clinically meaningful differences between biosimilar etanercept and the originator product in safety and efficacy over 52 weeks[1]
  • Innovative study design demonstrates switching between biosimilar etanercept and the originator product has no impact on safety and efficacy[1]
  • Sandoz biosimilar etanercept was approved by the FDA* in August 2016 and is currently under review by the EMA**

Holzkirchen, November 18, 2016 – Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today …

/by

Novartis delivered solid third quarter with Growth Products[1] offsetting Gleevec patent expiration; several positive readouts for potential blockbusters

  • Q3 net sales (-1% cc[2] and USD) broadly in line with prior year due to strong performance of Growth Products
    • Gilenya (USD 790 million, +15% cc) continued double-digit growth
    • Cosentyx (USD 301 million) on track for blockbuster status in first full year after approval
    • Oncology growth drivers including Tafinlar + Mekinist (USD 172 million, +29% cc), Promacta/Revolade (USD 168 million, +44% cc) and Jakavi (USD 149 million, +47% cc)
    • Sandoz Biopharmaceuticals[1] (USD 262 million, +41% cc) …
/by

Sandoz invites young entrepreneurs to enter Sandoz HACk, a global competition to help solve healthcare access challenges

  • Despite significant advances made by modern medicine, universal access to healthcare is still arguably the single largest unmet medical need
  • Sandoz “HACk” – Healthcare Access Challenge – is a competition seeking young people with innovative ideas to “reimagine” access to healthcare
  • Sandoz HACk is partnering with OpenIDEO – a global community that drives collaboration, innovation and impact around the world’s toughest problems

Holzkirchen, September 28, 2016 – Sandoz, the Novartis generic and biosimilar …

/by

Top-line results for PF-06438179 (biosimilar infliximab) demonstrate equivalent efficacy to reference product

  • Sandoz, a Novartis division, the pioneer and global leader in biosimilars acquired the rights from Pfizer for the development, commercialization and manufacture of PF-06438179 in the 28 countries that form the European Economic Area (EEA)* in February 2016 where it is known as GP1111.
  • The confirmatory study (REFLECTIONS B537-02), evaluating the efficacy, safety and immunogenicity of PF-06438179 (biosimilar infliximab) to reference product Remicade® (infliximab), met its primary endpoint.
  • Results demonstrate equivalent efficacy as measured by the American College of …
/by

AirFluSal® Forspiro® showed superiority at 12 months over Seretide® Diskus®[1] in persistence to treatment

  • New study shows that rate of patient persistence using Sandoz AirFluSal Forspiro is twice as high as for reference product Seretide® Diskus®.
  • Study highlights importance of improving treatment “persistence” over time for long-term respiratory diseases.
  • Analysis, published in leading medical journal, is largest European Real-World Evidence study ever conducted in asthma and COPD.

[1] Seretide® and Diskus® are registered trademarks owned by Glaxo Group Ltd.

Holzkirchen, August 31, 2016 – New data just …

/by